查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1517292

CDK2 抑制劑市場 – 管道分析（2024）

CDK2 Inhibitor - Pipeline Analytics 2024
出版日期: | 出版商: Mellalta Meets LLP | 英文 114 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

細胞週期蛋白依賴性激酶 2（CDK2）是控制細胞分裂和細胞週期的重要蛋白激酶。 CDK2 失調與多種癌症有關，使其成為治療幹預的有吸引力的目標。

CDK2 抑制劑代表了一個有吸引力的投資機會。這些抑制劑針對關鍵的細胞週期動態，為多種高負擔癌症類型（包括乳癌和卵巢癌）提供治療潛力。

CDK2 抑制劑市場充滿活力，競爭激烈，Sino Biopharma、Tiziana Life Sciences、Incyclix Bio、Pfizer、Cyclacel Pharmaceuticals、Blueprint Medicines等主要公司提供超過 36 種產品。這些公司研究 CDK2 抑制劑的各種適應症，包括 ER+/HER2 乳癌、非小細胞肺癌、去分化脂肪肉瘤、卵巢癌、不可切除/轉移性肝細胞癌和 CCNE1 擴增癌症。

憑藉強大的產品線和有前景的臨床資料，這些抑制劑代表了腫瘤學領域的高回報機會。許多具有CDK2抑制活性的小分子抑制劑已被鑑定。然而，這些抑制劑的開發充滿了挑戰，特別是由於細胞週期蛋白依賴性激酶（CDK）之間的結構相似性而導致的特異性。

CDK2抑制劑市場競爭激烈，有超過36種抑制劑。大部分處於早期階段，其中探索階段佔38.89%，臨床前階段佔19.44%，第一期產品佔19.44%。 %。

在主要進入者中，Blueprint Medicines 和輝瑞擁有最多的資產，共有三個投資組合。

本報告調查了全球 CDK2 抑制劑市場，並提供了市場現狀、病例量趨勢、患者趨勢、競爭產品市場定位和市場機會。

目錄

第1章 概述

第2章 CDK2抑制劑的標靶背景

  • CDK2抑制劑的介紹與作用
  • 對 CDK4/6 抑制劑的潛在擔憂
  • CDK2抑制劑：腫瘤學中極具前景的標靶
  • CDK2抑制劑的臨床應用
  • 克服 CDK4/6 抗藥性：CDK2 抑制劑的策略作用
  • CDK2抑制劑的變構機制

第3章 CDK2抑制劑管線的階段特異性分析

  • CDK2 抑制劑的開發 - 概述
  • 依開發階段劃分的管道產品
  • 各公司的管道產品
  • 依適應症和階段劃分的管道產品
  • CDK2抑制劑單藥及合併治療的臨床試驗
  • CDK2管道：臨床試驗的地理分佈
  • CDK2 抑制劑的臨床和監管時間表
  • 後期概況比較概述

第4章 CDK2 抑制劑授權、收購與合作協議

  • CDK2 抑制劑的授權、收購與交易價值
  • CDK2抑制劑許可交易類型和總規模

第5章 CDK2抑制劑管線狀況

  • CDK2 抑制劑研發管線的藥物概況 - 概述
    • 第三期
    • 第二期
    • 第一/二期
    • 第一期
    • 臨床前
    • 藥物發現

第6章 變構 CDK2 抑制劑的機制 - 概述

第7章 CDK2抑制劑的SWOT分析

第8章 附錄

簡介目錄

The 2024 Mellalta Meets report analyzes the CDK2 inhibitor pipeline landscape, highlighting the market opportunities and competitive landscape with over 32 companies developing pipeline drug profiles.

Cyclin-dependent kinase 2 (CDK2) is a pivotal protein kinase that orchestrates cell division and the cell cycle. Dysregulation of CDK2 has been implicated in various cancers, making it an attractive target for therapeutic intervention.

CDK2 inhibitors present a compelling investment opportunity. These inhibitors target critical cell cycle dynamics, offering therapeutic potential across multiple high-burden cancer types such as Breast and Ovarian Cancer.

The CDK2 inhibitor market is highly dynamic and competitive with over 36 products with key players, including Sino Biopharma, Tiziana Life Sciences, Incyclix Bio, Pfizer, Cyclacel Pharmaceuticals, and Blueprint Medicines. These companies are pursuing various indications for CDK2 inhibitors, such as ER+/HER2- breast cancer, non-small cell lung cancer, dedifferentiated liposarcoma, ovarian cancer, unresectable/metastatic hepatocellular carcinoma, and CCNE1-amplified cancers.

With a robust pipeline and promising clinical data, these inhibitors represent a high-reward opportunity in the oncology landscape. Numerous small molecule inhibitors have been identified for their CDK2 inhibitory activity. However, the development of these inhibitors is fraught with challenges, particularly regarding specificity due to the structural similarities among cyclin-dependent kinases (CDKs).

Efforts are ongoing to engineer inhibitors that selectively target CDK2, thereby minimizing off-target effects and enhancing therapeutic efficacy. As research progresses, CDK2 inhibitors are poised to play a transformative role in overcoming CDK4/6 resistance, offering significant benefits for patients and lucrative opportunities for investors with the usage of different CDK2 targeting strategies such as protein-protein interaction, Allosteric, Orthosteric, and indirect inhibition.

The CDK2 Inhibitor - Pipeline Analytics -2024 report published by Mellalta Meets covers the Cell Therapies market opportunity providing Key Competitive Analysis, 32+ Companies and 36 Products with Pipeline Drug Profiles, Clinical Trials, Other Developments (Collaboration Details, Funding, etc.), Licensing and Agreements, Business Agreement, Business Partner as well as Clinical Partner. Reports cover pipeline product analysis by stage of development, competitive landscape by phases, companies, clinical trials by regions, and intervention type. CDK2 Inhibitor-Pipeline Analytics report adds value in terms of describing clinical-stage products for their clinical & regulatory timelines as well as in terms of providing the current market opportunity, drivers, and challenges.

Mellalta's CDK2 Inhibitor Pipeline Report - Key Highlights

The CDK2 inhibitors market is highly competitive, with over 36 inhibitors. The majority are in the early stage, with 38.89% in the Discovery stage, 19.44% in the pre-clinical stage, and 19.44% in Phase 1. Phase 1/2 products make up 16.67% of the total, while Phase 3 and Phase 2 products each represent 2.78%.

Among the key players, Blueprint Medicines and Pfizer stand out with the highest number of assets, totaling three in its portfolio.

Allosteric inhibitors are favored and preferred mechanisms due to their low toxicity profiles.

Cyclins are being directly targeted as a focused approach to avoid toxicity.

Report Coverage:

Indication Prioritization: CDK2 Inhibitor market potential

Business Transactions & Strategies: Key collaborations and deal values

CDK2 Inhibitor Pipeline Development: Product Profiles, Clinical Trials & Results

CDK2 Inhibitor Acquisition Targets

CDK2 Inhibitor Competitive Intelligence

Recent and upcoming events

Table of Content

1. OVERVIEW

2. The CDK2 Inhibitor Target BACKGROUND

  • 2.1. Introduction and Role of CDK2 inhibitors
  • 2.2. Potential Concern with CDK4/6 Inhibitors
  • 2.3. CDK2 Inhibitors: A Highly-Potential Target in Oncology Space
  • 2.4. Clinical Applications of CDK2 Inhibitors
  • 2.5. Overcoming CDK4/6 Resistance: The Strategic Role of CDK2 Inhibitors
  • 2.6. Allosteric Mechanism of CDK2 Inhibitors

3. CDK2 Inhibitor PIPELINE ANALYSIS by Phases

  • 3.1. CDK2 Inhibitor Development - Overview
  • 3.2. Pipeline Products by Stage of Development
  • 3.3. Pipeline Products by Company
  • 3.4. Pipeline Products by Indication and Phases
  • 3.5. CDK2 Inhibitor Monotherapy & Combinations Clinical Trials
  • 3.6. CDK2 Pipeline: Geographic Distribution of Clinical Trials
  • 3.7. CDK2 Inhibitor Clinical & Regulatory Timelines
  • 3.8. Late-Stage Profiles Comparisons At-a-glance

4. CDK2 Inhibitor LICENSING, ACQUISITION, AND COLLABORATION DEALS

  • 4.1. CDK2 Inhibitor Licensing, Acquisition, and Deal values
  • 4.2. CDK2 Inhibitor Licensing by Transaction type and total amount size by Phases

5. CDK2 Inhibitor Pipeline Landscape

  • 5.1. CDK2 Inhibitor Pipeline Drug Profiles- at a glance
    • 5.1.1. Phase III
      • 5.1.1.1. TQB3616 (Sino Biopharma)
        • 5.1.1.1.1. Product Profile & Description
        • 5.1.1.1.2. Clinical Trials
        • 5.1.1.1.3. Collaborations
        • 5.1.1.1.4. Other Developments
    • 5.1.2. Phase II
      • 5.1.2.1. Milciclib (Tiziana Life Sciences)
        • 5.1.2.1.1. Product Profile & Description
        • 5.1.2.1.2. Clinical Trials
        • 5.1.2.1.3. Collaborations
        • 5.1.2.1.4. Other Developments
    • 5.1.3. Phase I/II
      • 5.1.3.1. INX-315 (Incyclix Bio)
        • 5.1.3.1.1. Product Profile & Description
        • 5.1.3.1.2. Clinical Trials
        • 5.1.3.1.3. Collaborations
        • 5.1.3.1.4. Other Developments
      • 5.1.3.2. Fadraciclib (Cyclacel Pharmaceuticals)
        • 5.1.3.2.1. Product Profile & Description
        • 5.1.3.2.2. Clinical Trials
        • 5.1.3.2.3. Collaborations
        • 5.1.3.2.4. Other Developments
      • 5.1.3.3. PF 07104091 (Pfizer)
        • 5.1.3.3.1. Product Profile & Description
        • 5.1.3.3.2. Clinical Trials
        • 5.1.3.3.3. Collaborations
        • 5.1.3.3.4. Other Developments
      • 5.1.3.4. AVZO-021 (Avenzo Therapeutics/Allorion Therapeutics Inc)
        • 5.1.3.4.1. Product Profile & Description
        • 5.1.3.4.2. Clinical Trials
        • 5.1.3.4.3. Collaborations
        • 5.1.3.4.4. Other Developments
      • 5.1.3.5. AZD 8421 (AstraZeneca)
        • 5.1.3.5.1. Product Profile & Description
        • 5.1.3.5.2. Clinical Trials
        • 5.1.3.5.3. Collaborations
        • 5.1.3.5.4. Other Developments
      • 5.1.3.6. BLU 222 (Blueprint Medicines)
        • 5.1.3.6.1. Product Profile & Description
        • 5.1.3.6.2. Clinical Trials
        • 5.1.3.6.3. Collaborations
        • 5.1.3.6.4. Other Developments
    • 5.1.4. Phase I
      • 5.1.4.1. NKT 3447 (NiKang Therapeutics)
        • 5.1.4.1.1. Product Profile & Description
        • 5.1.4.1.2. Clinical Trials
        • 5.1.4.1.3. Collaborations
        • 5.1.4.1.4. Other Developments
      • 5.1.4.2. BG-68501 (BeiGene)
        • 5.1.4.2.1. Product Profile & Description
        • 5.1.4.2.2. Clinical Trials
        • 5.1.4.2.3. Collaborations
        • 5.1.4.2.4. Other Developments
      • 5.1.4.3. TYK 0540 (TYK Medicine)
        • 5.1.4.3.1. Product Profile & Description
        • 5.1.4.3.2. Clinical Trials
        • 5.1.4.3.3. Collaborations
        • 5.1.4.3.4. Other Developments
      • 5.1.4.4. INCB123667 (Incyte)
        • 5.1.4.4.1. Product Profile & Description
        • 5.1.4.4.2. Clinical Trials
        • 5.1.4.4.3. Collaborations
        • 5.1.4.4.4. Other Developments
      • 5.1.4.5. RGT-419B (REGOR THERAPEUTICS)
        • 5.1.4.5.1. Product Profile & Description
        • 5.1.4.5.2. Clinical Trials
        • 5.1.4.5.3. Collaborations
        • 5.1.4.5.4. Other Developments
      • 5.1.4.6. SYH2043 (CSPC Ouyi Pharmaceutical)
        • 5.1.4.6.1. Product Profile & Description
        • 5.1.4.6.2. Clinical Trials
        • 5.1.4.6.3. Collaborations
        • 5.1.4.6.4. Other Developments
      • 5.1.4.7. WXWH0240 (Cisen Pharmaceutical)
        • 5.1.4.7.1. Product Profile & Description
        • 5.1.4.7.2. Clinical Trials
        • 5.1.4.7.3. Collaborations
        • 5.1.4.7.4. Other Developments
    • 5.1.5. Preclinical
      • 5.1.5.1. IAM-C1 (Iambic Therapeutics)
        • 5.1.5.1.1. Product Profile & Description
        • 5.1.5.1.2. Collaborations
        • 5.1.5.1.3. Other Developments
      • 5.1.5.2. AU14-5 (AUCENTRA)
        • 5.1.5.2.1. Product Profile & Description
        • 5.1.5.2.2. Collaborations
        • 5.1.5.2.3. Other Developments
      • 5.1.5.3. CID-078 (Circle Pharma)
        • 5.1.5.3.1. Product Profile & Description
        • 5.1.5.3.2. Collaborations
        • 5.1.5.3.3. Other Developments
      • 5.1.5.4. CC002 (Chupu Chuangzhi (Wuhan) Pharmaceutical Technology)
        • 5.1.5.4.1. Product Profile & Description
        • 5.1.5.4.2. Collaborations
        • 5.1.5.4.3. Other Developments
      • 5.1.5.5. IpY.20 (Concarlo Therapeutics)
        • 5.1.5.5.1. Product Profile & Description
        • 5.1.5.5.2. Collaborations
        • 5.1.5.5.3. Other Developments
      • 5.1.5.6. CED-2368 (Bayer)
        • 5.1.5.6.1. Product Profile & Description
        • 5.1.5.6.2. Collaborations
        • 5.1.5.6.3. Other Developments
      • 5.1.5.7. TY-1210 (TYK Medicines)
        • 5.1.5.7.1. Product Profile & Description
        • 5.1.5.7.2. Collaborations
        • 5.1.5.7.3. Other Developments
    • 5.1.6. Discovery
      • 5.1.6.1. CDK2 and CCNE1 (Kymera Therapeutics)
        • 5.1.6.1.1. Product Profile & Description
        • 5.1.6.1.2. Collaborations
        • 5.1.6.1.3. Other Developments
      • 5.1.6.2. CDK2 targeting therapeutics (Plexium)
        • 5.1.6.2.1. Product Profile & Description
        • 5.1.6.2.2. Collaborations
        • 5.1.6.2.3. Other Developments
      • 5.1.6.3. CDK2 Inhibitor (Bugworks)
        • 5.1.6.3.1. Product Profile & Description
        • 5.1.6.3.2. Collaborations
        • 5.1.6.3.3. Other Developments
      • 5.1.6.4. CDK2 degraders (Monte Rosa Therapeutics)
        • 5.1.6.4.1. Product Profile & Description
        • 5.1.6.4.2. Collaborations & Other Developments
      • 5.1.6.5. BLU-956 (Blueprint Medicines)
        • 5.1.6.5.1. Product Profile & Description
        • 5.1.6.5.2. Collaborations
        • 5.1.6.5.3. Other Developments
      • 5.1.6.6. TPD: CDK2 (Blueprint Medicines)
        • 5.1.6.6.1. Product Profile & Description
        • 5.1.6.6.2. Collaborations
        • 5.1.6.6.3. Other Developments
      • 5.1.6.7. QR-6401 (REGOR THERAPEUTICS)
        • 5.1.6.7.1. Product Profile & Description
        • 5.1.6.7.2. Collaborations
        • 5.1.6.7.3. Other Developments
      • 5.1.6.8. CDK2 inhibitor (Calibr-Skaggs)
        • 5.1.6.8.1. Product Profile & Description
        • 5.1.6.8.2. Collaborations
        • 5.1.6.8.3. Other Developments
      • 5.1.6.9. Cyclin E/CDK2 inhibitor (Circle Pharma)
        • 5.1.6.9.1. Product Profile & Description
        • 5.1.6.9.2. Collaborations
        • 5.1.6.9.3. Other Developments
      • 5.1.6.10. TMX-2172 (Dana-Farber Cancer Institute)
        • 5.1.6.10.1. Product Profile & Description
        • 5.1.6.10.2. Collaborations
        • 5.1.6.10.3. Other Developments
      • 5.1.6.11. CDK2 Inhibitor (Acellera Therapeutics)
        • 5.1.6.11.1. Product Profile & Description
        • 5.1.6.11.2. Collaborations
        • 5.1.6.11.3. Other Developments
      • 5.1.6.12. FP19711 and FP24322 (Fog Pharma)
        • 5.1.6.12.1. Product Profile & Description
        • 5.1.6.12.2. Collaborations
        • 5.1.6.12.3. Other Developments
      • 5.1.6.13. I-125A and I-198 (Pfizer/ Belharra Therapeutics/ Magnet Biomedicine)
        • 5.1.6.13.1. Product Profile & Description
        • 5.1.6.13.2. Collaborations
        • 5.1.6.13.3. Other Developments

6. Allosteric CDK2 Inhibitor Mechanisms- At a glance

7. CDK2 Inhibitor SWOT Analysis

8. Appendix